Abbott Laboratories (ABT)
ABT moved a median of -0.05% 30 minutes after news, and +0.03% by the close. How ABT actually reacts to news — the realized, point-in-time move the market made, measured across 438 labeled events over the last three years with zero look-ahead.
ABT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 53% | 438 |
| 30-min | -0.05% | 48% | 438 |
| 60-min | -0.10% | 45% | 438 |
| to close | +0.03% | 50% | 437 |
| Middle 50% of ABT reactions | -0.47% to +0.47% |
|---|---|
| Median reaction (30-min) | -0.05% |
| Measured reactions | 438 |
Half of all Abbott Laboratories news events land between -0.47% and +0.47% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | +0.31% | 65% | +0.27% |
| Coverage initiations | 18 | +0.43% | 83% | -0.40% |
| Rating reiterations | 122 | +0.01% | 53% | +0.10% |
| Price-target raises | 55 | +0.01% | 53% | -0.13% |
| Price-target cuts | 55 | +0.51% | 66% | +0.01% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how ABT ranks against every other measured name →
That’s how ABT usually reacts — get an email when it moves on news →Email me when ABT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABT's baseline. Nothing else.
Recent ABT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula | Press release | PR Newswire | -0.75% | -1.06% | |
| Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke | Press release | PR Newswire | +0.12% | -1.03% | |
| Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes | Press release | PR Newswire | +0.09% | +0.16% | |
| Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants | Press release | PR Newswire | +0.69% | +2.30% | |
| Form 8-K ABBOTT LABORATORIES For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +2.30% | |
| Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare | Press release | PR Newswire | -0.14% | -0.18% | |
| First Bellwether Trial Today Against Reckitt Benckiser’s Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio | Press release | Business Wire | +1.20% | +0.51% | |
| Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis | Press release | PR Newswire | +0.79% | +2.63% | |
| Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI | Press release | PR Newswire | +0.99% | +1.17% | |
| Form 10-Q ABBOTT LABORATORIES For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.48% | +0.96% | |
| Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance | Press release | PR Newswire | +3.71% | +3.63% | |
| Form 8-K ABBOTT LABORATORIES For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +3.71% | +3.63% | |
| Abbott hosts conference call for second-quarter earnings | Press release | PR Newswire | +1.47% | +2.27% | |
| ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing | Press release | PR Newswire | +0.96% | -0.89% | |
| New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents | Press release | PR Newswire | +0.20% | -0.29% | |
| Form 11-K ABBOTT LABORATORIES For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.15% | +0.09% | |
| Abbott declares 410th consecutive quarterly dividend | Press release | PR Newswire | +0.20% | +0.97% | |
| New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers | Press release | PR Newswire | -0.17% | -0.43% | |
| New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis | Press release | PR Newswire | -0.17% | -0.43% | |
| Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes | Press release | PR Newswire | +0.61% | +1.18% | |
| Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes | Press release | PR Newswire | -0.88% | -1.28% | |
| ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening | Press release | PR Newswire | -0.88% | -1.28% | |
| Form SD ABBOTT LABORATORIES | SEC filing · Form SD | SEC EDGAR | +0.61% | +1.18% | |
| Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 | Press release | PR Newswire | +0.35% | +0.66% | |
| Form 10-Q ABBOTT LABORATORIES For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.19% | -0.52% | |
| Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform | Press release | PR Newswire | +0.44% | +0.05% | |
| Form 8-K ABBOTT LABORATORIES For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | +0.05% | |
| Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 | Press release | PR Newswire | +1.14% | +2.11% | |
| Form S-8 ABBOTT LABORATORIES | SEC filing · Form S-8 | SEC EDGAR | +1.14% | +2.11% | |
| Form 8-K ABBOTT LABORATORIES For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | -0.52% | |
| New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test | Press release | PR Newswire | +0.10% | +0.11% | |
| Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences | Press release | PR Newswire | +0.34% | -1.58% | |
| Form 8-K ABBOTT LABORATORIES For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -1.58% | |
| New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health | Press release | PR Newswire | -0.09% | +0.07% | |
| Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform | Press release | PR Newswire | -1.37% | -2.52% | |
| Abbott hosts conference call for first-quarter earnings | Press release | PR Newswire | +0.12% | -0.03% | |
| John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening | Press release | PR Newswire | -0.80% | +0.33% | |
| Abbott completes acquisition of Exact Sciences | Press release | PR Newswire | -0.58% | -1.35% | |
| Form 8-K ABBOTT LABORATORIES For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -1.35% | |
| Form S-8 ABBOTT LABORATORIES | SEC filing · Form S-8 | SEC EDGAR | -0.80% | +0.33% | |
| Abbott acquisition of Exact Sciences set to close on March 23, 2026 | Press release | PR Newswire | -0.25% | -1.87% | |
| Form ARS ABBOTT LABORATORIES For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.29% | +0.98% | |
| Form DEF 14A ABBOTT LABORATORIES For: Apr 24 | SEC filing · Form DEF | SEC EDGAR | +0.29% | +0.98% | |
| Form DEFA14A ABBOTT LABORATORIES | SEC filing · Form DEFA14A | SEC EDGAR | +0.29% | +0.98% | |
| Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management | Press release | PR Newswire | +0.14% | -1.49% | |
| Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' | Press release | PR Newswire | -0.35% | -0.22% | |
| Form 8-K ABBOTT LABORATORIES For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -1.27% | |
| Trial Set in NEC Multidistrict Litigation Against Reckitt Benckiser’s Mead Johnson Led by Levin Papantonio | Press release | Business Wire | +0.13% | -0.47% | |
| Form 8-K ABBOTT LABORATORIES For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | +0.19% | |
| Form S-3ASR ABBOTT LABORATORIES | SEC filing · Form S-3ASR | SEC EDGAR | +0.59% | +2.81% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABT section they belong to.
Where else ABT is measured.
ABT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Globus Medical, Inc. Class A (GMED) | 439 | +0.01% | 50% |
| Zymeworks Inc. (ZYME) | 439 | 0.00% | 50% |
| Arvinas, Inc. (ARVN) | 438 | -0.26% | 42% |
| Charles River Laboratories International, Inc. (CRL) | 438 | -0.10% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Abbott Laboratories's median reaction calculated?
Every labeled ABT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 438 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ABT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ABT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.